Cartesian Therapeutics Inc. (RNAC) — Capital Reinvestment Ratio
Cartesian Therapeutics Inc. (RNAC) has a Capital Reinvestment Ratio of 0.45x as of September 2024, meaning it reinvests 0% of its operating cash flow ($13.69 Million) in capital expenditures ($6.20 Million). See Cartesian Therapeutics Inc. (RNAC) balance sheet quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Cartesian Therapeutics Inc. Capital Reinvestment Ratio (2020–2020)
This chart tracks Cartesian Therapeutics Inc.'s Capital Reinvestment Ratio across 1 annual periods. Check how aggressively does Cartesian Therapeutics Inc. reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Cartesian Therapeutics Inc. (2020–2020)
Year-by-year Capital Reinvestment Ratio for Cartesian Therapeutics Inc. from 2020 to 2020. For live market cap and broader valuation context, see RNAC market cap overview.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.02x | $34.88 Million | $815.00K | — |